Contents

PIER: ranibizumab for neovascular age-related macular degeneration

September 1, 2010

Clinical trial

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.

Abraham P, Yue H, Wilson L.

Am J Ophthalmol. 2010 Sep;150(3):315-324.e1.
Full text | Metrics.

Main finding: Ranibizumab provided significant VA benefit in patients with CNV secondary to AMD compared to sham.

 

  • Purpose: To evaluate efficacy and safety of quarterly (and then monthly) ranibizumab in subjects with subfoveal CNV with or without classic CNV secondary to AMD.
  • Study type: Randomized clinical trial
  • Condition: CNV secondary to AMD

Participants: ≥50yo, primary or recurrent subfoveal CNV (predominantly classic, minimally classic, or occult with no classic) from AMD, BCV 20/40-20/320

 

  • n=184

 

Intervention:

 

Group 1: sham injection
Group 2: Intravitreal ranibizumab 0.3mg
Group 3: Intravitreal ranibizumab 0.5mg

VA of sham patients who crossed over to ranibizumab had an average loss of 3.5 letters 10 months after crossover.

 

VA of ranibizumab 0.3 mg and 0.5 mg group patients who rolled over to monthly ranibizumab increased on average by 2.2 and 4.1 letters, respectively, 4 months after rollover.

Outcomes Sham injection IVR 0.3mg IVR 0.5mg
VA change (letters) from baseline -21.4 -2.2 -2.3

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed